Bliesath
Joshua Bliesath, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090133136 | Inducible SIRNA expression cassette and method of use - An inducible siRNA expression polynucleotide and methods for its use are provided. The expression polynucleotide comprises a bicistronic expression cassette that encodes a repressor and a detectable marker, wherein the repressor controls expression of siRNA expression in the absence of an inducer. | 05-21-2009 |
Joshua R. Bliesath, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20100331256 | Variants of C-Type Natriuretic Peptides - The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and/or substitutions with natural amino acids, unnatural amino acids and/or peptidomimetics (including peptide bond isosteres); amino acid extensions; and/or other chemical moieties such as, e.g., poly(ethylene glycol) and hydrophobic acids. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders such as, e.g., skeletal dysplasias and achondroplasia, and vascular smooth muscle disorders such as, e.g., restenosis and arteriosclerosis. | 12-30-2010 |
Joshua R. Bliesath, Escondido, CA US
Patent application number | Description | Published |
---|---|---|
20100173013 | TREATMENT OF NEOPLASTIC DISORDERS USING COMBINATION THERAPIES - The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders. | 07-08-2010 |
20110212845 | Biomarkers for predicting the sensitivity and response of protein kinase CK2-mediated diseases to CK2 Inhibitors - Disclosed are biomarkers for determining the sensitivity of protein kinase CK2-mediated diseases, such as proliferative and/or inflammatory disorders, to treatment with CK2 inhibitors. These biomarkers can be used to predict or select subjects likely to be responsive to treatment with a CK2 inhibitor, and to treat or monitor subjects undergoing treatment with a CK2 inhibitor. | 09-01-2011 |